Pacira BioSciences, Inc. (PCRX) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Pacira BioSciences’s revenue went from $276M in fiscal 2016 to $726M in fiscal 2025, growth of about 11.3% a year.
Net income in fiscal 2025 was $7M, a net margin of 1.0%; the best year in this period was 2020 with $146M.
Over the twelve months to September 30, 2026, revenue was $743M and net income $38M.
Free cash flow was $137M in fiscal 2025 and positive in 9 of the 10 years shown.
The diluted share count rose 21% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $743M | $726M | $701M | $675M | $667M | $542M | $430M | $421M | $337M | $287M | $276M |
| Gross profit | — | $577M | $531M | $490M | $468M | $401M | $312M | $314M | $250M | $199M | $166M |
| Operating income | $36M | $19M | -$73M | $88M | $60M | $90M | $46M | $10M | $16M | -$25M | -$32M |
| Net income | $38M | $7M | -$100M | $42M | $16M | $42M | $146M | -$11M | -$471000 | -$43M | -$38M |
| EPS (diluted) | $0.93 | $0.16 | $-2.15 | $0.89 | $0.34 | $0.92 | $3.33 | $-0.27 | $-0.01 | $-1.07 | $-1.02 |
| R&D | $122M | $117M | $82M | $76M | $85M | $56M | $59M | $72M | $56M | $57M | $46M |
| Revenue growth | — | +3.6% | +3.9% | +1.2% | +23.1% | +26.0% | +2.1% | +24.8% | +17.7% | +3.7% | +11.0% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $177M | $152M | $189M | $155M | $145M | $126M | $77M | $71M | $49M | $18M | $33M |
| Capital spending | -$8M | -$15M | -$11M | -$15M | -$30M | -$46M | -$38M | -$10M | -$15M | -$19M | -$25M |
| Free cash flow | $169M | $137M | $179M | $139M | $115M | $80M | $39M | $60M | $34M | -$1M | $9M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $98M | $148M | $25M | $0 | $0 | — | — | — | — | — | — |
| Stock-based pay | $54M | $58M | $51M | $48M | $48M | $42M | $40M | $34M | $32M | $32M | $31M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $238M | $485M | $279M | $289M | $656M | $522M | $292M | $383M | $311M | $173M |
| Debt | — | $418M | $639M | $586M | $763M | $419M | $391M | $352M | $291M | $276M | $227M |
| Equity | — | $693M | $778M | $870M | $775M | $730M | $620M | $355M | $321M | $279M | $219M |
| Total assets | — | $1.3B | $1.6B | $1.6B | $1.7B | $2.1B | $1.3B | $831M | $689M | $628M | $391M |
| Shares (diluted) | 41M | 45M | 46M | 52M | 47M | 46M | 44M | 42M | 41M | 40M | 37M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 79.4% | 75.7% | 72.6% | 70.1% | 74.1% | 72.7% | 74.7% | 74.2% | 69.3% | 60.2% |
| Operating margin | 4.8% | 2.6% | -10.5% | 13.0% | 9.0% | 16.6% | 10.8% | 2.5% | 4.7% | -8.7% | -11.6% |
| Net margin | 5.1% | 1.0% | -14.2% | 6.2% | 2.4% | 7.8% | 33.9% | -2.6% | -0.1% | -14.9% | -13.7% |
| FCF margin | 22.7% | 18.8% | 25.5% | 20.7% | 17.3% | 14.8% | 9.1% | 14.3% | 10.2% | -0.5% | 3.2% |
| ROIC | — | 1.4% | -4.1% | 4.1% | 3.1% | 5.8% | 3.6% | 1.2% | 2.1% | -3.5% | -5.7% |
| ROE | — | 1.0% | -12.8% | 4.8% | 2.1% | 5.8% | 23.5% | -3.1% | -0.1% | -15.2% | -17.3% |
Frequently asked questions
What is Pacira BioSciences’s annual revenue?
$726M in fiscal 2025 and $743M over the twelve months to September 30, 2026.
How much profit does Pacira BioSciences make?
Net income was $7M in fiscal 2025 (net margin 1.0%).
Is Pacira BioSciences’s revenue growing?
Yes: revenue rose 3.6% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.